Maryam Oskoui



Director, Division of Pediatric Neurology, Department of Pediatric, Montreal Children’s Hospital

Associate Professor, Departments of Pediatrics and Neurology and Neurosurgery, McGill University | Scientist, Research Institute of the McGill University Health Centre

NMD4C Working Group(s): Knowledge Translation

Email Maryam


Dr. Maryam Oskoui is a pediatric neurologist, neurophysiologist and epidemiologist. She is a Clinician Scientist and Director of Pediatric Neurology at the Montreal Children’s Hospital. She is a Senior Clinical Research Scholar of the FRQ-S with a focus in clinical research and clinical trials in pediatric neuromuscular disorders and has contributed to over 100 peer reviewed publications. She is a Principal investigator and SMA lead for INFORM RARE, a Strategy for Patient Oriented Research innovative clinical trial initiative supported by CIHR.


Dr. Oskoui serves as an evidence-based methodologist for the American Academy of Neurology and has contributed to numerous clinical care guidelines. As part of NMD4C, she is developing clinical guidelines through the Knowledge Translation Team. She contributes to the Canadian Neuromuscular community by serving as a member of the Scientific Advisory Committee for Muscular Dystrophy Canada and chairing the Canadian Pediatric Neuromuscular Group and the Canadian Neuromuscular Disease Registry’s Spinal Muscular Atrophy Working Group. She is a Board member for the Association des Neurologues du Quebec.


Dr. Oskoui completed her medical school and pediatric neurology residency at McGill University (Montreal, Canada), neuromuscular clinical and research fellowship at Columbia University (New York, USA) and Master’s of Science in Clinical Epidemiology at McGill University.

Recent Publications

Mirchi, A, Richer, J, Oskoui, M, McMillan, HJ. NTRK1-related Hereditary Sensory and Autonomic Neuropathy Type 4: The Role of the Histamine Challenge Test. Child Neurol Open. .9 2329048X221108826 PMID:35756968

Kim, DH, Elsherbini, N, Zielinski, D, Oskoui, M. A Case Report of Systemic Intoxication Following Onabotulinum Toxin A Injections Into the Salivary Glands in a Patient With Spinal Muscular Atrophy Type 1. Pediatr Neurol. 2022.129 37-38 PMID:35217275

Mercuri, E, Deconinck, N, Mazzone, ES, Nascimento, A, Oskoui, M, Saito, K et al.. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022.21 (1)42-52 PMID:34942136

Rudnicki, SA, Andrews, JA, Duong, T, Cockroft, BM, Malik, FI, Meng, L et al.. Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study. Neurotherapeutics. 2021.18 (3)2130 PMID:34731415

Oskoui, M, Potter, BK. Methodological challenges in measuring meaningful change in individuals with spinal muscular atrophy. Muscle Nerve. 2021.64 (6)639-640 PMID:34687231

See more on PubMed